Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvelestat in Alpha-1 Antitrypsin Deficiency
NCT03636347Phase 2Completed
- Sponsor
- Mereo BioPharma
- Start
- Oct 2018
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of alvelestat in alpha-1 antitrypsin deficiency (AATD), sponsored by Mereo BioPharma. Started Oct 2018; status: completed.
02
Drugs
alvelestat
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT03636347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03636347.